Abiraterone, an Inhibitor of Cytochrome P 17, Effective in Hormone Refractory Prostate Cancer

Published on Wednesday 30 July 2008 - 15:51

Summary :
Researchers from the United Kingdom have reported that the selective inhibitor of CYP17, abiraterone acetate, may be effective for the treatment of hormone refractory prostate cancer (HRPC). These...
Read more

Information source

Cancer Consultants Cancer News for Professionals

http://rss.cancerconsultants.com/ProFeed.aspx

Website description
Professional Cancer News from all disease categories.

Articles published on this website : 0 / 7 days - 0 / 30 days

MRI with Contrast Effective for Pelvic Lymph Node Watchful Waiting Versus Radical Prostatectomy: 11-year Follow-up U.S. Preventive Service Task Force Does Not Recommend Denosumab Improves Bone Density in Prostate Cancer Patients Study Questions Benefit of Androgen Deprivation Therapy for

Other articles published on other websites on the same day

Saw Palmetto's Safety Confirmed http://www.stopagingnow.com/ Anavex presents neuroprotective effects of Anavex 1-41 at the International Conference on Alzheimer's Disease 2008 http://www.foxbusiness.com/ Robotic surgery extends benefits to bladder cancer patients at NewYork-Presbyterian/Weill Cornell http://www.physorg.com/ Cancer diary: ‘I’m going to live until I die’ http://www.msnbc.msn.com/ A novel treatment for advanced prostate cancer http://www.healthjockey.com/ Hormone Therapy In Prostate Cancer Treatment May Lead To Cognitive Decline http://www.emaxhealth.com/ Pints for Prostates Delivers Men's Health Message Using the Universal Language of Beer http://www.dawsontimes.com/ Combine Existing Prostate Cancer Drugs With New Ones at Lower Doses for Better Results, Say Australian Doctors http://www.medindia.com/ New treatment for advanced prostate cancer developed http://www.newstrackindia.com/ Gender inequality in cancer-screening leave http://timesunion.com/